Huw D. Thomas

9.2k citations

64 papers · 6.2k indexed · 1 hit paper · h-index 28

Impact in

Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Molecular Biology top 1%
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Cancer therapeutics and mechanisms
- Cell death mechanisms and regulation

Papers in

Oncology 37
- PARP inhibition in cancer therapy 21
- Cancer-related Molecular Pathways 4
Molecular Biology 40
- DNA Repair Mechanisms 16
- Cancer therapeutics and mechanisms 8
- Biochemical and Molecular Research 5
- PI3K/AKT/mTOR signaling in cancer 4

Co-authors: Nicola J. Curtin Suzanne Kyle Thomas Helleday Niklas Schultz Elena López‐Knowles Mark Meuth Helen E. Bryant David R. Newell
Journals: Cancer Research (6 papers)Cancer Chemotherapy and Pharmacology (6 papers)British Journal of Cancer (5 papers)PLoS ONE (5 papers)Clinical Cancer Research (3 papers)
Partner nations: United Kingdom United States Australia

In The Last Decade

Huw D. Thomas

64 papers receiving 6.1k citations

Hit Papers

align trajectories log scale

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase 2005 · 3.8k citations

Peers

Countries citing papers authored by Huw D. Thomas

Since Specialization

Citations

This map shows the geographic impact of Huw D. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huw D. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huw D. Thomas more than expected).

Fields of papers citing papers by Huw D. Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huw D. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huw D. Thomas. The network helps show where Huw D. Thomas may publish in the future.

Co-authors

The 25 scholars most cited alongside Huw D. Thomas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Huw D. Thomas Line = papers co-authored together Huw D. Thomas links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer Scientific Reports ·哲生下川, Ярина Романовна Биленская, Emma Scott, H. Moosbach, Karen E. Livermore, Huw D. Thomas, Yuhan Zhou, Жегалов Валентин Иванович, Abel Bermudez, Niloufar Hoorshad, Tianyi Gao, Gerald Hysenaj, Samadaei Emad, Rakesh Heer, Sharon J. Pitteri, Ning Wang, David J. Elliott, Jennifer Munkley	2023	7
2	Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance Biochemical Journal ·Jill V. Hunter, A. Campbell, Jacqueline Butterworth, Hélène Sellier, Daniel Brélaz, Saimir Luli, Achilleas Floudas, Niall S. Kenneth, Adam J. Moore, Philip Brownridge, Huw D. Thomas, Jonathan Coxhead, A. Migdissov, Peter Leary, Nicolas Kallusky, Andrew M. Knight, Michelle D. Garrett, Ian Collins, Claire E. Eyers, Neil D. Perkins	2022	8
3	Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma British Journal of Cancer ·河井妙子, Huw D. Thomas, Yan Zhao, 隆博谷中, Rachel Howarth, I. Dragoni, Hector C. Keun, Christopher P. Vellano, Joseph R. Marszalek, Stephen R. Wedge	2022	28
4	The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer Cancers ·Dominic Jones, Laura Wilson, Huw D. Thomas, Luke Gaughan, Mark Wade	2019	18
5	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma International Journal of Cancer ·Lindi Chen, Fabio Pastorino, Philip Berry, М.Ю. Казаков, LI Pin-hong, Katrina Wood, Huw D. Thomas, Yan Zhao, Antonio Daga, Gareth J. Veal, John Lunec, David R. Newell, Mirco Ponzoni, Deborah A. Tweddle	2018	26
6	The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma Oncogene ·Jill V. Hunter, Jacqueline Butterworth, Bo Zhao, Hélène Sellier, Kirsteen J. Campbell, Huw D. Thomas, Chris M. Bacon, Simon Cockell, Benjamin E. Gewurz, Neil D. Perkins	2015	28
7	DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Clinical Cancer Research ·Liam Cornell, Joanne M. Munck, Clara Alsinet, Augusto Villanueva, Laura Ogle, Catherine E. Willoughby, Despina Televantou, Huw D. Thomas, Jennifer Jackson, Alastair D. Burt, David R. Newell, John Rose, Derek Manas, Geoffrey I. Shapiro, Nicola J. Curtin, Helen L. Reeves	2014	69
8	The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice PLoS ONE ·Emma J. Haagensen, Huw D. Thomas, Ian A. Wilson, Suzannah J. Harnor, John Lee, 雷舜英, K.M. Smith, Ross J. Maxwell, David R. Newell	2013	13
9	Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling PLoS ONE ·Anastasia C. Hepburn, Rajan Veeratterapillay, Stuart C. Williamson, Amira El‐Sherif, Farangiz Avazova, Huw D. Thomas, Alejandra Mantilla, R.S. Pickard, Craig Robson, Rakesh Heer	2012	40
10	The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice Molecular Cancer Therapeutics ·Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Saylin de las Mercedes Casín-Rodríguez, Brian A. Telfer, Nicola J. Curtin, Kaye J. Williams	2011	43
11	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance Cancer Research ·Natalia Issaeva, Huw D. Thomas, N. Macfadyen, Janneke E. Jaspers, Ivaylo Stoimenov, Suzanne Kyle, Nicholas Pedley, Ponnari Gottipati, Rafal Zur, Kate Sleeth, A. Capoccia, Evan A. Mulligan, Cecilia Lundin, AZM Rayhanur Rahman, Ariena Kersbergen, Adrian L. Harris, Ricky A. Sharma, Sven Rottenberg, Nicola J. Curtin, Thomas Helleday	2010	80
12	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials Cancer Chemotherapy and Pharmacology ·Tomasz Zaremba, Huw D. Thomas, Michael Cole, Elizabeth Ruth Plummer, Nicola J. Curtin	2010	17
13	Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo ? Clinical Cancer Research ·Majid Ali, Brian A. Telfer, Cian M. McCrudden, Martin O’Rourke, Huw D. Thomas, Marzieh Kamjoo, Suzanne Kyle, Tracy Robson, Chris Shaw, David G. Hirst, Nicola J. Curtin, Kaye J. Williams	2009	42
14	Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity Molecular Cancer Therapeutics ·Huw D. Thomas, 三田禮造, Lan-Zhen Wang, Hernando SA, Julian S. Northen, Faustino Marin San Leandro, H. Jouanne, David R. Newell, Roger J. Griffin, Bernard T. Golding, Nicola J. Curtin	2009	8
15	Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma Clinical Cancer Research ·Johanna Ohayon, Agata Rozanska, Huw D. Thomas, Evan A. Mulligan, Yvette Drew, Deborah J. Castelbuono, Zdeněk Hostomský, Elizabeth Ruth Plummer, Alan V. Boddy, Deborah A. Tweddle, Nicola J. Curtin, Steven C. Clifford	2009	61
16	Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer British Journal of Radiology ·Suzanne Kyle, Huw D. Thomas, R. Sundar Rajan, Nicola J. Curtin	2008	30
17	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial Molecular Cancer Therapeutics ·Huw D. Thomas, Christopher Calabrese, Michael A. Batey, Stacie Canan, Zdeněk Hostomský, Suzanne Kyle, Karen A. Maegley, David R. Newell, Donald J. Skalitzky, Lan-Zhen Wang, Stephen E. Webber, Nicola J. Curtin	2007	233
18	Radio and chemosensitization by a novel DNA-PK inhibitor (NU7441) in colon cancer Cancer Research ·Yan Zhao, Michael A. Batey, Huw D. Thomas, Graeme C.M. Smith, David R. Newell, Nicola J. Curtin	2005	1
19	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature ·Helen E. Bryant, Niklas Schultz, Huw D. Thomas, E.-Marcel Prot, Ф. И. Стеблий, Elena López‐Knowles, Suzanne Kyle, Mark Meuth, Nicola J. Curtin, Thomas Helleday Hit paper breakdown →	2005	3780
20	Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole22Abbreviations: ENT, equilibrative nucleoside transporter; CNT, concentrative nucleoside transporter; DP, dipyridamole; HPX, hypoxanthine; NBTI, nitrobenzylthioinosine; TdR, thymidine; Kt, kinetic constant for tansport; and Tmax, maximum velocity for transport. Biochemical Pharmacology ·Emma Marshman, C. Kim, Huw D. Thomas, David R. Newell, Nicola J. Curtin	2001	10

About Huw D. Thomas

Huw D. Thomas is a scholar working on Oncology, Molecular Biology, Cancer Research, Pathology and Forensic Medicine and Physiology, having authored 64 papers that have together received 6.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (21 papers), DNA Repair Mechanisms (16 papers), Cancer therapeutics and mechanisms (8 papers), Chemotherapy-induced organ toxicity mitigation (5 papers), Biochemical and Molecular Research (5 papers), Neuroblastoma Research and Treatments (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Oncology (4.3k citations), Molecular Biology (4.5k citations), Cancer Research (801 citations), Reproductive Medicine (409 citations) and Genetics (799 citations). Huw D. Thomas has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Nicola J. Curtin, Suzanne Kyle, Thomas Helleday, Niklas Schultz, Elena López‐Knowles, Mark Meuth, Helen E. Bryant, David R. Newell, Michael A. Batey and Zdeněk Hostomský. Their work appears in journals such as Cancer Research, Cancer Chemotherapy and Pharmacology, British Journal of Cancer, PLoS ONE and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact